AAQ1 Stock Overview
aap Implantate AG develops, manufactures, and markets trauma products for orthopedics.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
aap Implantate AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.32 |
| 52 Week High | €1.59 |
| 52 Week Low | €0.65 |
| Beta | -0.053 |
| 1 Month Change | 87.23% |
| 3 Month Change | 80.82% |
| 1 Year Change | 3.13% |
| 3 Year Change | -53.85% |
| 5 Year Change | -88.32% |
| Change since IPO | -98.71% |
Recent News & Updates
Recent updates
Shareholder Returns
| AAQ1 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 16.8% | -1.0% | 1.9% |
| 1Y | 3.1% | -5.0% | 4.6% |
Return vs Industry: AAQ1 exceeded the German Medical Equipment industry which returned -5% over the past year.
Return vs Market: AAQ1 underperformed the German Market which returned 4.6% over the past year.
Price Volatility
| AAQ1 volatility | |
|---|---|
| AAQ1 Average Weekly Movement | 18.9% |
| Medical Equipment Industry Average Movement | 4.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AAQ1's share price has been volatile over the past 3 months.
Volatility Over Time: AAQ1's weekly volatility has increased from 13% to 19% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 111 | Rubino Di Girolamo | www.aap.de |
aap Implantate AG develops, manufactures, and markets trauma products for orthopedics. It offers LOQTEQ, an anatomical plating system for fracture treatment of ankle joint, knee, elbow, and shoulder; and a range of cannulated screws. The company sells its products directly to hospitals, purchasing groups, and hospital groups in Germany, and through a network of distributors internationally.
aap Implantate AG Fundamentals Summary
| AAQ1 fundamental statistics | |
|---|---|
| Market cap | €13.11m |
| Earnings (TTM) | -€2.31m |
| Revenue (TTM) | €11.96m |
1.1x
P/S Ratio-5.7x
P/E RatioIs AAQ1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AAQ1 income statement (TTM) | |
|---|---|
| Revenue | €11.96m |
| Cost of Revenue | €1.47m |
| Gross Profit | €10.49m |
| Other Expenses | €12.80m |
| Earnings | -€2.31m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.23 |
| Gross Margin | 87.72% |
| Net Profit Margin | -19.32% |
| Debt/Equity Ratio | 8.1% |
How did AAQ1 perform over the long term?
See historical performance and comparison